SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-038295
Filing Date
2023-11-09
Accepted
2023-11-09 16:39:57
Documents
50
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20230930.htm   iXBRL 10-Q 1294684
2 EX-31.1 ex-311x20230930.htm EX-31.1 9694
3 EX-31.2 ex-312x20230930.htm EX-31.2 9685
4 EX-32.1 ex-321x20230930.htm EX-32.1 9556
  Complete submission text file 0001628280-23-038295.txt   5285386

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20230930.xsd EX-101.SCH 31154
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20230930_cal.xml EX-101.CAL 52836
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20230930_def.xml EX-101.DEF 189769
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20230930_lab.xml EX-101.LAB 461574
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20230930_pre.xml EX-101.PRE 287525
44 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20230930_htm.xml XML 604182
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 231393273
SIC: 2834 Pharmaceutical Preparations